The device was used to detect exosome subtypes expressing CD24, EpCAM, and FRalpha proteins in 2 μL plasma samples from 20 ovarian cancer patients and to suggest exosomal FRalpha as a promising biomarker in the early detection and monitoring of ovarian cancer progression. This evidence concerns the gene FOLR1 and ovarian carcinoma.